文献速递淋巴瘤

慢性淋巴细胞白血病一线化学免疫治疗后高灵敏度可测量残留病灶评估的预后价值

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
PubMed 文献 · Leukemia · 2020-09-15

基于FILO三项临床试验(CLL2007FMP、CLL2007SA、CLL2010FMP)的汇总分析,在401例外周血和339例骨髓样本中评估高灵敏度(0.7×10⁻⁵)流式细胞术MRD检测的预后价值。中位随访49.5个月,结果显示外周血高灵敏度MRD阴性较低水平阳性(<0.01%)显著延长PFS(72.2 vs 42.7个月,HR 0.40,p=0.0003),而骨髓检测未显示此差异。

要点

  • 外周血高灵敏度MRD阴性较低水平阳性(<0.01%)显著延长PFS(72.2 vs 42.7个月,HR 0.40,p=0.0003)。
  • 将低水平阳性MRD(<0.01%)纳入阳性定义后,外周血阳性比例增加39%,骨髓增加27%。
  • 外周血任何水平MRD阳性均与较短PFS相关,不受临床完全或部分缓解及IGHV突变状态影响(均p<0.05)。

核心结论

  • 外周血高灵敏度(0.0007%)MRD评估较现行标准灵敏度(0.01%)提供额外预后信息。

研究设计与样本

  • 基于FILO组三项试验(CLL2007FMP、CLL2007SA、CLL2010FMP)的汇总分析。
  • 纳入接受FCR为基础化学免疫治疗的同质人群,中位随访49.5个月。
  • 采用流式细胞术检测外周血(N=401)和骨髓(N=339)样本,灵敏度0.7×10⁻⁵。

主要发现

  • 将低水平阳性MRD(<0.01%)加入MRD≥0.01%后,外周血阳性比例增加39%,骨髓增加27%。
  • 外周血高灵敏度MRD阴性较低水平阳性(<0.01%)显著延长PFS(72.2 vs 42.7个月;HR 0.40,p=0.0003),骨髓未显示此差异。
  • 外周血任何水平MRD阳性较阴性均与较短PFS相关,不受临床缓解状态及IGHV突变状态影响(均p<0.05)。

临床怎么用

  • 在CLL一线化学免疫治疗后,可考虑采用外周血高灵敏度MRD检测(0.7×10⁻⁵)以获取额外预后信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD < 0.01% to MRD ≥ 0.01% increased the proportion of cases with positive MRD in blood by 39% and in bone marrow by 27%. Compared to low-level positive MRD < 0.01%, undetectable MRD was associated with significantly longer progression-free survival (PFS) when using blood (72.2 versus 42.7 months; hazard ratio 0.40, p = 0.0003), but not when using bone marrow. Upon further stratification, positive blood MRD at any level, compared to undetectable blood MRD, was associated with shorter PFS irrespective of clinical complete or partial remission, and a lower 5-year PFS rate irrespective of IGHV-mutated or -unmutated status (all p < 0.05). In conclusion, high-sensitivity (0.0007%) MRD assessment in blood yielded additional prognostic information beyond the current standard sensitivity (0.01%). Our approach provides a model for future determination of the optimal MRD investigative strategy for any regimen.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Letestu R, Dahmani A, Boubaya M, et al. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. Leukemia. 2020. PMID: 32934355. doi:10.1038/s41375-020-01009-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。